The size of the gemcitabine resistant market (gemcitabine resistant pancreatic and bladder cancers) is approximately $4-8 billion per year. Initially RX-3117 may be used in patients that have already become resistant to gemcitabine. However, because of the improved efficacy and safety of RX-3117 (as compared to gemcitabine), it may have the ability to replace gemcitabine in the treat